0I5P Stock Overview
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CymaBay Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.48 |
| 52 Week High | US$32.51 |
| 52 Week Low | US$7.32 |
| Beta | 0.32 |
| 1 Month Change | 0.90% |
| 3 Month Change | 38.79% |
| 1 Year Change | 264.98% |
| 3 Year Change | 639.95% |
| 5 Year Change | n/a |
| Change since IPO | 179.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0I5P | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0.1% | 2.5% | 1.6% |
| 1Y | 265.0% | -3.6% | 4.6% |
Return vs Industry: 0I5P exceeded the UK Pharmaceuticals industry which returned 0.7% over the past year.
Return vs Market: 0I5P exceeded the UK Market which returned 3.1% over the past year.
Price Volatility
| 0I5P volatility | |
|---|---|
| 0I5P Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0I5P's share price has been volatile over the past 3 months.
Volatility Over Time: 0I5P's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 101 | Sujal Shah | www.cymabay.com |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes.
CymaBay Therapeutics, Inc. Fundamentals Summary
| 0I5P fundamental statistics | |
|---|---|
| Market cap | US$3.73b |
| Earnings (TTM) | -US$105.37m |
| Revenue (TTM) | US$31.07m |
120.0x
P/S Ratio-35.4x
P/E RatioIs 0I5P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0I5P income statement (TTM) | |
|---|---|
| Revenue | US$31.07m |
| Cost of Revenue | US$80.80m |
| Gross Profit | -US$49.73m |
| Other Expenses | US$55.64m |
| Earnings | -US$105.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | -160.03% |
| Net Profit Margin | -339.10% |
| Debt/Equity Ratio | 37.4% |
How did 0I5P perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/22 16:41 |
| End of Day Share Price | 2024/03/22 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CymaBay Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Julian Harrison | BTIG |
| John Tanner | Cantor Fitzgerald & Co. |